Role of albumin in the treatment of decompensated liver cirrhosis.
Journal
Current opinion in gastroenterology
ISSN: 1531-7056
Titre abrégé: Curr Opin Gastroenterol
Pays: United States
ID NLM: 8506887
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
12
3
2022
medline:
7
6
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
Albumin has been used primarily as a plasma expander, since it leads to an increase in the circulating blood volume. Current generally recommended indications for albumin therapy in cirrhotic patients are the prevention of circulatory dysfunction after large-volume paracentesis, the prevention of hepatorenal syndrome (HRS) in patients with spontaneous bacterial peritonitis (SBP), and the management of HRS in combination with vasoconstrictors. Yet, new indications for albumin have been tested in the recent years and are outlined in this short review. New data show that albumin both supports the circulation and reduces systemic inflammation. In addition, to its oncotic function, it acts as an antioxidant, radical scavenger, and immune modulator. These nononcotic properties explain why long-term albumin administration in patients with decompensated cirrhosis may be useful in the prevention of associated complications (acute-on-chronic liver failure, infections). New data show that long-term albumin therapy in patients with cirrhosis and ascites improves survival, prevents complications, simplifies ascites management, and lowers hospitalization rates. The so-called disease-modifying effects of long-term albumin therapy may have a favorable effect on the course of the disease. Nevertheless, the optimal dosage and administration intervals have not yet been finally defined. Albumin therapy is effective in the indications already recommended by the guidelines. A possible extension of the indication for albumin administration in non-SBP infections and as long-term therapy is promising, but should be confirmed by further studies.
Identifiants
pubmed: 35275900
doi: 10.1097/MOG.0000000000000838
pii: 00001574-202205000-00004
doi:
Substances chimiques
Albumins
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
200-205Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Strauss AW, Donohue AM, Bennett CD, et al. Rat liver preproalbumin: in vitro synthesis and partial amino acid sequence. Proc Natl Acad Sci USA 1977; 74:1358–1362.
Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol 2014; 61:396–407.
Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646–649.
Domenicali M, Baldassarre M, Giannone FA, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 2014; 60:1851–1860.
Naldi M, Baldassarre M, Nati M, et al. Mass spectrometric characterization of human serum albumin dimer: a new potential biomarker in chronic liver diseases. J Pharm Biomed Anal 2015; 112:169–175.
Alcaraz-Quiles J, Casulleras M, Oettl K, et al. Oxidized albumin triggers a cytokine storm in leukocytes through P38 mitogen-activated protein kinase: role in systemic inflammation in decompensated cirrhosis. Hepatology 2018; 68:1937–1952.
Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8:1151–1157.
Arroyo V, Angeli P, Moreau R, et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol 2021; 74:670–685.
Trebicka J, Fernandez J, Papp M, et al. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol 2021; 74:1097–1108.
Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastro-enterol Hepatol 2021; 18:167–180.
Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct patho-physiology. J Hepatol 2020; 73:842–854.
Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144:1426–1437. 1437 e1421-1429.
Moreau R, Claria J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol 2020; 72:688–701.
Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut 2020; 69:1127–1138.
Casulleras M, Flores-Costa R, Duran-Guell M, et al. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decom-pensated cirrhosis. Sci Transl Med 2020; 12:eaax5135.
Duran-Guell M, Flores-Costa R, Casulleras M, et al. Albumin protects the liver from tumor necrosis factor alpha-induced immunopathology. FASEB J 2021; 35:e21365.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69:406–460.
Gerbes AL, Labenz J, Appenrodt B, et al. Updated S2k-Guideline ‘Complications of liver cirrhosis’. German Society of Gastroenterology (DGVS). Z Gastroenterol 2019; 57:611–680.
Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 74:1014–1048.
Trebicka J, Reiberger T, Laleman W. Gut-liver axis links portal hypertension to acute-on-chronic liver failure. Visc Med 2018; 34:270–275.
Fernandez J, Claria J, Amoros A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology 2019; 157:149–162.
Claria J, Moreau R, Fenaille F, et al. Orchestration of Tryptophan-Kynurenine Pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis. Hepatology 2019; 69:1686–1701.
Fernandez J, Angeli P, Trebicka J, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2020; 18: 963-973.e914.
O’Brien AJ, Fullerton JN, Massey KA, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med 2014; 20:518–523.
China L, Freemantle N, Forrest E, et al. A Randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 2021; 384:808–817.
Luca A, Garcia-Pagan JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995; 22:753–758.
Arora V, Vijayaraghavan R, Maiwall R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure. Hepatology 2020; 72:1043–1055.
Ortega R, Gines P, Uriz J, et al. Terlipressin therapywith and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrando-mized study. Hepatology 2002; 36:941–948.
Guevara M, Terra C, Nazar A, et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol 2012; 57:759–765.
Thevenot T, Bureau C, Oberti F, et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol 2015; 62:822–830.
Garcia-Martinez R, Andreola F, Mehta G, et al. Immunomodulatory and anti-oxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. J Hepatol 2015; 62:799–806.
Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018; 391:2417–2429.
Di Pascoli M, Fasolato S, Piano S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int 2019; 39:98–105.
Sola E, Sole C, Simon-Talero M, et al. Midodrine and albumin for pre-vention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol 2018; 69:1250–1259.
Jalan R, Bernardi M. Effective albumin concentration and cirrhosis mortality: from concept to reality. J Hepatol 2013; 59:918–920.